# Low-threshold buprenorphine treatment at syringe services programs: a Type I hybrid effectiveness-implementation trial” (CTN concept under development)

> **NIH NIH UG1** · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2024 · $9,879

## Abstract

Tookes’ Supplement Request
Abstract
Most Americans with OUD remain out-of-treatment. Over the past three decades, rates of opioid use, OUD and
overdose have skyrocketed. Medications for opioid use disorder (MOUD), including methadone and BUP, are
the first-line OUD treatments; however, in 2019, after years of Medicaid expansion and MOUD implementation
initiatives, only 1 million of the 7.6 million persons in the US in need of OUD treatment received MOUD, leaving
a large treatment gap. Barriers to MOUD are often structural, including availability, health system
fragmentation, wait times and healthcare providers’ stigma toward people who use drugs (PWUD). Therefore,
structural interventions are needed to increase MOUD access and use. BUP treatment is associated with large
reductions in overdose-related mortality. However, strong racial/ethnic and geographic disparities in BUP
access have emerged with marginalized groups have more limited access to care. “Low-threshold” BUP
models seek to increase BUP access by offering same-day treatment entry, flexibility, harm reduction
counseling, and availability in unconventional settings, such as emergency departments, mobile units, or harm
reduction agencies. The proposed study, Low-threshold buprenorphine treatment at syringe services
programs: a Type I hybrid effectiveness-implementation trial, targets structural barriers to BUP treatment (e.g.,
health system fragmentation, waiting lists, and medical providers’ stigma towards people with OUD) by
integrating BUP treatment into syringe services programs (SSPs). Dr Hansel Tookes from the Florida Node
Alliance will serve as Co-Lead Investigator and will dedicate effort to protocol development activities.

## Key facts

- **NIH application ID:** 11127166
- **Project number:** 3UG1DA013720-25S2
- **Recipient organization:** UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
- **Principal Investigator:** Daniel J Feaster
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $9,879
- **Award type:** 3
- **Project period:** 2024-09-15 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11127166

## Citation

> US National Institutes of Health, RePORTER application 11127166, Low-threshold buprenorphine treatment at syringe services programs: a Type I hybrid effectiveness-implementation trial” (CTN concept under development) (3UG1DA013720-25S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11127166. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*